Geneos Wealth Management Inc. Boosts Stock Position in Eli Lilly and Company (NYSE:LLY)

Key Points

• Geneos Wealth Management Inc. increased its stake in Eli Lilly and Company by 34.4%, holding 11,537 shares valued at approximately $9.53 million as of the latest SEC filing.
• Analyst ratings for Eli Lilly are mixed, with Goldman Sachs upgrading the stock to a "buy" while HSBC downgraded its rating, highlighting varied outlooks among analysts.
• Eli Lilly announced a quarterly dividend of $1.50 per share, resulting in an annualized dividend of $6.00 and a yield of 0.74%, reflecting the company's ongoing commitment to return capital to shareholders.

Geneos Wealth Management Inc. raised its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 34.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,537 shares of the company's stock after buying an additional 2,956 shares during the quarter. Geneos Wealth Management Inc.'s holdings in Eli Lilly and Company were worth $9,528,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently made changes to their positions in the business. Geode Capital Management LLC increased its position in shares of Eli Lilly and Company by 1.7% during the fourth quarter. Geode Capital Management LLC now owns 17,382,846 shares of the company's stock valued at $13,389,651,000 after acquiring an additional 291,875 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Eli Lilly and Company by 103,831.6% during the first quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company's stock worth $12,278,292,000 after buying an additional 14,852,076 shares during the period. Wellington Management Group LLP boosted its position in Eli Lilly and Company by 19.0% during the fourth quarter. Wellington Management Group LLP now owns 12,625,925 shares of the company's stock valued at $9,747,214,000 after purchasing an additional 2,012,129 shares in the last quarter. Capital Research Global Investors lifted its holdings in shares of Eli Lilly and Company by 16.1% during the fourth quarter. Capital Research Global Investors now owns 10,757,511 shares of the company's stock worth $8,304,811,000 after purchasing an additional 1,493,673 shares during the period. Finally, Northern Trust Corp lifted its holdings in Eli Lilly and Company by 14.6% in the fourth quarter. Northern Trust Corp now owns 9,448,219 shares of the company's stock valued at $7,294,025,000 after acquiring an additional 1,204,337 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

LLY stock traded down $3.19 during midday trading on Wednesday, reaching $759.76. 4,331,834 shares of the company were exchanged, compared to its average volume of 3,787,427. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53. The firm has a market capitalization of $720.05 billion, a price-to-earnings ratio of 61.82, a price-to-earnings-growth ratio of 1.15 and a beta of 0.40. The business has a 50-day moving average price of $773.36 and a two-hundred day moving average price of $800.41. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.37 and a quick ratio of 1.06.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). The company had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The company's revenue for the quarter was up 45.2% on a year-over-year basis. During the same period last year, the firm posted $2.58 earnings per share. Equities research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be paid a $1.50 dividend. The ex-dividend date is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.79%. Eli Lilly and Company's dividend payout ratio is presently 48.82%.

Analysts Set New Price Targets

A number of brokerages have issued reports on LLY. Guggenheim boosted their target price on Eli Lilly and Company from $936.00 to $942.00 and gave the company a "buy" rating in a research report on Friday, July 11th. The Goldman Sachs Group raised Eli Lilly and Company from a "neutral" rating to a "buy" rating and reduced their price target for the company from $892.00 to $888.00 in a report on Tuesday, April 8th. HSBC downgraded Eli Lilly and Company from a "buy" rating to a "reduce" rating and reduced their target price for the stock from $1,150.00 to $700.00 in a research report on Monday, April 28th. Cantor Fitzgerald started coverage on Eli Lilly and Company in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price target on the stock. Finally, Erste Group Bank lowered shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, June 5th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and a consensus price target of $1,012.56.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.